ReviewGene2021
Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19.
Review in Gene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Advancing COVID-19 Treatment: The Role of Non-covalent Inhibitors Unveiled by Integrated Machine Learning and Network Pharmacology.Current pharmaceutical design · 2025Article
- Alterations in Circadian Rhythms, Sleep, and Physical Activity in COVID-19: Mechanisms, Interventions, and Lessons for the Future.Molecular neurobiology · 2024Review
- The role of epithelial-mesenchymal transition in pulmonary fibrosis: lessons from idiopathic pulmonary fibrosis and COVID-19.Cell communication and signaling : CCS · 2024Review
- Host factors of SARS-CoV-2 in infection, pathogenesis, and long-term effects.Frontiers in cellular and infection microbiology · 2024Review
- Article
- Impairment of antiviral immune response and disruption of cellular functions by SARS-CoV-2 ORF7a and ORF7b.iScience · 2022Article
- Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interaction.Scientific reports · 2022Article
- Structure/Function Analysis of Truncated Amino-Terminal ACE2 Peptide Analogs That Bind to SARS-CoV-2 Spike Glycoprotein.Molecules (Basel, Switzerland) · 2022Article
- In Silico Insights towards the Identification of SARS-CoV-2 NSP13 Helicase Druggable Pockets.Biomolecules · 2022Article
- Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Cyanobacteria and Algae-Derived Bioactive Metabolites as Antiviral Agents: Evidence, Mode of Action, and Scope for Further Expansion; A Comprehensive Review in Light of the SARS-CoV-2 Outbreak.Antioxidants (Basel, Switzerland) · 2022Review
- Geographical Appraisal of COVID-19 in West Bengal, India.GeoJournal · 2022Article
- Human genetic basis of coronavirus disease 2019.Signal transduction and targeted therapy · 2021Review
- A computational study of cooperative binding to multiple SARS-CoV-2 proteins.Scientific reports · 2021Article
- Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate.ACS medicinal chemistry letters · 2021Article
- Discovery of naturally occurring inhibitors against SARS-CoV-2 3CLFitoterapia · 2021Article
- Estrogen Receptor Modulators in Viral Infections Such as SARS-CoV-2: Therapeutic Consequences.International journal of molecular sciences · 2021Review
- Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2.Journal of pharmaceutical sciences · 2021Article
- Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations.European journal of pharmacology · 2021Article
- One year update on the COVID-19 pandemic: Where are we now?Acta tropica · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The whole world is still suffering substantially from the coronavirus disease 2019 (COVID-19) outbreak. Several protein-based molecules that are associated with the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which are essential for its functionality, survival, and pathogenesis have been identified and are considered as potential therapeutic targets. These protein-based molecules are either structural/non-structural components of SARS-CoV-2 or host factors, which play a crucial role in this infection. Developing drug molecules against these essential functional molecules to hinder their regular functioning and associated physiological pathways could be promising for successful clinical management of this novel coronavirus infection. The review aims to highlight the functional molecules that play crucial roles in SARS-CoV-2 pathogenesis. We have emphasized how these potential druggable targets could be beneficial in tackling the COVID-19 crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.